Advertisement

Spencer Pharmaceutical Inc., a metabolic disease-focused firm in Boston, has announced that the unsolicited cash buyout offer it received last week is priced at 97 cents per share, which could bring the company $245 million.

The unnamed buyer has indicated a plan to take Spencer Pharmaceuticals (PINK: SPPH) private, according to Spencer officials, which have not revealed the name of the potential buyer and are awaiting approval from the board of directors.

SOURCE

Advertisement
Advertisement